X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7196) 7196
Book Review (724) 724
Publication (513) 513
Conference Proceeding (13) 13
Book Chapter (9) 9
Magazine Article (7) 7
Dissertation (3) 3
Book / eBook (1) 1
Newspaper Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (6804) 6804
humans (4299) 4299
animals (3751) 3751
male (3550) 3550
thiazoles - pharmacology (2560) 2560
thiazoles - administration & dosage (2473) 2473
female (2401) 2401
thiazoles - therapeutic use (2026) 2026
rats (1742) 1742
pharmacology & pharmacy (1697) 1697
mice (1343) 1343
dose-response relationship, drug (1273) 1273
adult (1247) 1247
middle aged (1184) 1184
thiazoles - adverse effects (1108) 1108
administration, oral (874) 874
aged (801) 801
thiazoles - pharmacokinetics (801) 801
thiazoles (784) 784
treatment outcome (696) 696
time factors (637) 637
neurosciences (635) 635
oncology (584) 584
thiazoles - chemistry (570) 570
thiazolidinediones (570) 570
rats, sprague-dawley (562) 562
tetrazolium salts (542) 542
analysis (530) 530
dasatinib (530) 530
abridged index medicus (523) 523
cell line, tumor (507) 507
meloxicam (459) 459
drug therapy (441) 441
double-blind method (438) 438
biochemistry & molecular biology (429) 429
research (429) 429
rats, wistar (416) 416
in-vitro (411) 411
psychiatry (402) 402
thiazines - administration & dosage (402) 402
pharmacokinetics (398) 398
disease models, animal (392) 392
piperazines - therapeutic use (390) 390
cancer (389) 389
care and treatment (381) 381
chemistry, medicinal (379) 379
apoptosis (377) 377
expression (374) 374
drug therapy, combination (362) 362
adolescent (360) 360
cell survival - drug effects (355) 355
drug administration schedule (353) 353
cells, cultured (350) 350
hematology (348) 348
thiazoles - metabolism (329) 329
piperazines - administration & dosage (324) 324
double-blind (315) 315
efficacy (315) 315
thiazoles - blood (310) 310
drug interactions (305) 305
dosage and administration (303) 303
endocrinology & metabolism (303) 303
article (292) 292
anti-inflammatory agents, non-steroidal - administration & dosage (290) 290
apoptosis - drug effects (288) 288
dogs (287) 287
antipsychotic agents - therapeutic use (285) 285
pyrimidines - administration & dosage (283) 283
toxicology (282) 282
schizophrenia (278) 278
pyrimidines - therapeutic use (271) 271
therapy (269) 269
medicine & public health (268) 268
pyridines - administration & dosage (268) 268
imatinib mesylate (266) 266
cells (265) 265
drugs (263) 263
piperazines - adverse effects (260) 260
diabetes mellitus, type 2 - drug therapy (255) 255
benzothiazoles (254) 254
veterinary sciences (254) 254
clinical neurology (253) 253
mice, inbred c57bl (252) 252
cell line (251) 251
antineoplastic agents - pharmacology (250) 250
inhibition (250) 250
health aspects (248) 248
pharmacology/toxicology (247) 247
young adult (245) 245
structure-activity relationship (244) 244
aged, 80 and over (243) 243
cell proliferation - drug effects (239) 239
thiazolidines (232) 232
hypoglycemic agents - therapeutic use (231) 231
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (231) 231
in-vivo (230) 230
antipsychotic agents - adverse effects (228) 228
pyridines - pharmacology (228) 228
hypoglycemic agents - pharmacology (227) 227
antineoplastic agents - therapeutic use (226) 226
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6934) 6934
Japanese (56) 56
German (55) 55
Russian (47) 47
French (26) 26
Italian (21) 21
Chinese (19) 19
Spanish (16) 16
Hungarian (9) 9
Polish (6) 6
Danish (5) 5
Czech (3) 3
Bulgarian (2) 2
Hebrew (2) 2
Portuguese (2) 2
Swedish (2) 2
Dutch (1) 1
Finnish (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2429 - 2438
Summary Background The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI),... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | PHARMACOKINETICS | SAFETY | NAIVE HIV-1-INFECTED PATIENTS | TREATMENT-EXPERIENCED PATIENTS | EFAVIRENZ | ADULTS | ANTIRETROVIRAL THERAPY | SINGLE-TABLET REGIMEN | PATIENTS 96-WEEK EFFICACY | COMBINATION | HIV-1 | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Atazanavir Sulfate | Adult | Female | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Ritonavir - administration & dosage | Deoxycytidine - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Quinolones - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Patient outcomes | Dosage and administration | Research | Comparative analysis | Drug therapy | HIV infection | Anti-HIV agents | Antiretroviral drugs | Bone density | Pharmaceutical industry | Human immunodeficiency virus--HIV | Pneumonia | Laboratories | Ritonavir | Liver | Infections | Drug resistance | Hepatitis | Randomization | All terrain vehicles | Creatinine | Integrase | Data processing | Proteinase inhibitors | Behavior disorders | Ribonucleic acid--RNA | Patients | Cholesterol | Glomerular filtration rate | Inhibitors | Protease inhibitors | Interactive systems | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2439 - 2448
Summary Background The integrase inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and... 
Internal Medicine | NON-INFERIORITY | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | RALTEGRAVIR | TREATMENT-EXPERIENCED PATIENTS | DISOPROXIL FUMARATE | ADULTS | ANTIRETROVIRAL THERAPY | SINGLE-TABLET REGIMEN | RILPIVIRINE | TREATMENT-NAIVE PATIENTS | Emtricitabine | HIV-1 | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Deoxycytidine - administration & dosage | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Adenine - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Organophosphonates - administration & dosage | Quinolones - administration & dosage | Adult | Female | HIV Infections - drug therapy | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Patient outcomes | Dosage and administration | Research | Comparative analysis | Drug therapy | HIV infection | Anti-HIV agents | Clinical trials | Antiretroviral drugs | Pharmaceutical industry | Human immunodeficiency virus--HIV | Creatinine | Integrase | Laboratories | Data processing | Infections | Nausea | Ribonucleic acid--RNA | Patients | Efavirenz | Dreams | Sleep disorders | Hepatitis | Dyspnea | Inhibitors | Protease inhibitors | Insomnia | Suicides & suicide attempts | Index Medicus | Abridged Index Medicus
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 32 - 39
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind,... 
T lymphocytes | HIV/AIDS | Antiretrovirals | Infectious diseases | RNA | HIV | Drug evaluation | AIDS | Photographs | HIV 1 | Virology | cobicistat | pharmacoenhancer | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | RENAL-FUNCTION | INITIAL TREATMENT | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | DAILY LOPINAVIR/RITONAVIR | GLOMERULAR-FILTRATION-RATE | EFAVIRENZ | DOUBLE-BLIND | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Research | Drug therapy | HIV infection | Patient outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 08/2013, Volume 122, Issue 7, pp. 1214 - 1221
From 2001 to 2011, 122 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia were treated with chemotherapy + imatinib (n... 
ADULT PATIENTS | HYPER-CVAD | GENE REARRANGEMENTS | STANDARD-RISK | QUANTIFICATION | ACUTE LYMPHOBLASTIC-LEUKEMIA | FLOW-CYTOMETRY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | CLINICAL-SIGNIFICANCE | Piperazines - administration & dosage | Cyclophosphamide - administration & dosage | Prognosis | Follow-Up Studies | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Thiazoles - administration & dosage | Neoplasm Recurrence, Local - mortality | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Benzamides - administration & dosage | Flow Cytometry | Neoplasm, Residual - diagnosis | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Neoplasm, Residual - mortality | Philadelphia Chromosome | Real-Time Polymerase Chain Reaction | Doxorubicin - administration & dosage | Dasatinib | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Pyrimidines - administration & dosage | RNA, Messenger - genetics | Survival Rate | Reverse Transcriptase Polymerase Chain Reaction | Imatinib Mesylate | Remission Induction | Cytarabine - administration & dosage | Neoplasm, Residual - genetics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | Immunoglobulin Heavy Chains - genetics | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 2014, Volume 111, Issue 5, pp. 981 - 988
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9987, pp. 2606 - 2615
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide... 
Internal Medicine | KIDNEY-DISEASE | RATES | MEDICINE, GENERAL & INTERNAL | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | SAFETY | ADULTS | ANTIRETROVIRAL THERAPY | LOPINAVIR/RITONAVIR | COUNT | EXPOSURE | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Arthralgia - chemically induced | Thiazoles - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Tenofovir | Adenine - adverse effects | Quinolones - adverse effects | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Headache - chemically induced | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Respiration Disorders - chemically induced | Double-Blind Method | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Nausea | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Quinolones - administration & dosage | Carbamates - adverse effects | HIV Infections - drug therapy | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Clinical trials | Cross infection | Nosocomial infections | HIV (Viruses) | Drug therapy | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Infections | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Index Medicus | Abridged Index Medicus
Journal Article